Drugs targeting SNPrs35753505 of the NGR1 gene may prevent the association of neurological disorder schizophrenia in a Pakistani population

CNS and Neurological Disorders - Drug Targets

Volumn 13, Issue 9, 2014, Pages 1604-1614

  Nawaz, Rukhsana ^a   Asif, Huma ^b   Khan, Asifullah ^c   Ishtiaq, Hina ^a   Shad, Fatima ^d   Siddiqui, Sonia ^a  

^a UNIVERSITY OF KARACHI   (Pakistan)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c ABDUL WALI KHAN UNIVERSITY   (Pakistan)

^d UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Adenine (A); Allele; DNA; Frequencies; Guanine (G); Hardy Weinberg equilibrium; Neuregulin 1; Schizophrenia; Single nucleotide polymorphism

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEU DIFFERENTIATION FACTOR; PROCYCLIDINE;

ADULT; ALLELE; ARTICLE; CHI SQUARE TEST; CHILD; CLINICAL EXAMINATION; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDER; DISEASE CLASSIFICATION; DNA POLYMORPHISM; DNA SEQUENCE; DRUG TARGETING; ELECTROPHORESIS; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC LINKAGE; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; GENOTYPING TECHNIQUE; HUMAN; ICD-10; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PSYCHIATRIST; QUESTIONNAIRE; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84920591399     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527313666140806150440     Document Type: Article

References (54)

1. Harris JM, Whalley H, Yates S, et al. Abnormal cortical folding in high-risk individuals: a predictor of the development of schizophrenia? Biol Psychiatry 2004; 56: 182-9.
2. Savage RM, Wiener HW, Nimgaonkar V, et al. Schizophr Res J 2012; 139(1-3): 105-9.
3. Stephan KE, Friston KJ, Frith CD. Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophr Bull 2009; 35: 509-27.
4. Kunii Y, Hyde TM, Ye T, et al. Revisiting DARPP-32 in postmortem human brain: changes in schizophrenia and bipolar disorder and genetic associations with t-DARPP-32 expression. Mol Psychiatry 2013; 10: 174.
5. Stephan KE, Friston KJ, Frith CD. Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring. Schizophrenia Bull 2009; 35: 509-27.
6. Kunii Y, Hyde TM, Ye T, et al. Revisiting DARPP-32 in postmortem human brain: changes in schizophrenia and bipolar disorder and genetic associations with t-DARPP-32 expression. Mol Psychiatry 2013; 10: 174.
7. Rethelyi JM, Benkovits J, Bitter I. Genes and environments in schizophrenia: The different pieces of a manifold puzzle. Neurosci Biobehav Rev 2013; 7634: 00106-1.
8. Thompson M, Lauderdale S, Webster MJ, et al. Widespread expression of ErbB2, ErbB3 and ErbB4 in non-human primate brain. Brain Res 2007; 1139: 95-109.
9. Rosa A, Gardner M, Cuesta MJ, et al. Family-based association study of neuregulin-1 gene and psychosis in a Spanish sample. Am J Med Genet B Neuropsychiatry Genet 2007; 144: 954-7.
10. Petryshen T, Middleton F, Kirby A, et al. Support for involvement of neuregulin 1 in schizophrenia pathophysiology. Mol Psychiatry 2004; 10: 366-74.
11. Duan J, Martinez M, Sanders AR, Hou C. Neuregulin 1 (NRG1) and schizophrenia: analysis of a US family sample and the evidence in the balance. Psychol Med 2005; 35: 1599-610.
12. Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immunity 2011; 25: 181-213.
13. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 2005; 10: 40-68.
14. Hashimoto R, Arion D, Unger T, et al. Alterations in GABA related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 2008; 13: 147-61.
15. Selemon LD, Goldman-Rakic PS. The reduced neuropil hypothesis: A circuit based model of schizophrenia. Biol Psychiatry 1999; 45: 17-25.
16. Erickson SL, Lewis DA. Cortical connections of the lateral mediodorsal thalamus in cynomolgus monkeys. J Comp Neurol 2004; 473: 107-27.
17. Dudkin KN, Kruchinin VK, Chueva IV. Neurophysiological correlates of delayed visual differentiation tasks in monkeys: the effects of the site of intracortical blockade of NMDA receptors. Neurosci Behav Physiol 2001; 31: 207-18.
18. Hahn CG, Wang HY, Cho DS, et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 2006; 12: 734-5.
19. Jones EG. Cortical development and thalamic pathology in schizophrenia. Schizophrenia Bull 1997; 23: 483-501.
20. Volk DW, Austin MC, Pierri JN, Sampson AR, Lewis DA. GABA transporter-1 mRNA in the prefrontal cortex in schizophrenia: Decreased expression in a subset of neurons. Am J Psychiatry 2001; 158: 256-65.
21. Hashimoto T, Volk DW, Eggan SM, et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J Neurosci 2003; 23: 6315-26.
22. Goldman-Rakic PS, Castner SA, Svensson TH, Siever LJ, Williams GV. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology 2004; 174: 3-16.
23. Akil M, Pierri JN, Whitehead RE, et al. Lamina-specific alterations in the dopamine innervation of the prefrontal cortex in schizophrenic subjects. Am J Psychiatry 1999; 156: 1580-9.
24. Karoutzou G, Emrich HM, Dietrich DE. The myelin-pathogenesis puzzle in schizophrenia: a literature review. Mol Psychiatry 2008; 13: 245-60.
25. Fields RD. White matter in learning, cognition and psychiatric disorders. Trends Neurosci 2008; 31: 361-70.
26. Martin LF, Freedman R. Schizophrenia and the alpha7 nicotinic acetylcholine receptor. Int Rev Neurobiol 2007; 78: 225-46.
27. Stefansson H, Steinthorsdottir V, Thorgeirsson TH, Gulcher JR, Stefansson K. Neuregulin 1 and schizophrenia. Trends Mol Med 2004; 36: 62-71.
28. Li D, Collier DA, He L. Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Hum Mol Genet 2006; 15: 1995-2002.
29. Kim JW, Lee YS, Cho EY, et al. Linkage and association of schizophrenia with genetic variations in the locus of neuregulin 1 in Korean population. Am J Med Genet Part B Neuropsychiatric Genet 2006; 141: 281-6.
30. Thompson M, Lauderdale S, Webster MJ, et al. Widespread expression of ErbB2, ErbB3 and ErbB4 in non-human primate brain. Brain Res 2007; 1139: 95-109.
31. Rosa A, Gardner M, Cuesta MJ, et al. Family-based association study of neuregulin-1 gene and psychosis in a Spanish sample. Am J Med Genet B Neuropsychiatry Genet 2007; 144: 954-7.
32. Ikeda M, Takahashi N, Saito S, et al. Failure to replicate the association between NRG1 and schizophrenia using Japanese large sample. Schizophrenia Res J 2008; 101(1-3): 1-8.
33. Chao Deng, Bo Pan, Martin Engel, Xu-Feng Huang. Neuregulin-1 signalling and antipsychotic treatment. Psychopharmacology 2013; 226: 201-15.
34. Bao J. Signal Transduction by the Cytoplasmic Domain of NEUREGULIN-1 and its Roles during Neuronal Aging. Curr Signal Transd Ther 2007; 2(3): 240-5. (b) Barceloux DG Manganese. Clin Toxicol 1999; 37: 293-307.
35. Coyle JT, Tsai G, Goff D. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann NY Acad Sci 2003; 1003: 318-27.
36. Andrea S, Jiri K, Mathias Z, et al. Gene expression of NMDA receptor subunits in the cerebellum of elderly patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2010; 260: 101-11.
37. Dean B. The cortical serotonin2A receptor and the pathology of schizophrenia: a likely accomplice. J Neurochem 2003; 85: 1-13.
38. Mark JM. N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives. Psychopharmacology 2003; 179: 30-53.
39. Jiri H, Vera BV, Milan K, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. Cent Nerv Syst Drug 2006; 179: 30-53.
40. Hashimoto R, Straub RE, Weickert CS, et al. Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. Mol Psychiatry 2004; 9: 299-307.
41. Lahiri DK, Nurnberger JI. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991; 19: 5444.
42. Stefansson H, Sigurdsson E, Steinthorsdottir V, et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 2002; 71: 877-92.
43. Stefansson H, Sarginson J, Kong A, et al. Association of neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet 2003; 72: 83-7.
44. Li T, Stefansson H, Gudfinnsson E, et al. Identification of a novel neuregulin 1 at-risk haplotype in Han schizophrenia Chinese patients, but no association with the Icelandic/Scottish risk haplotype. Mol Psychiatry 2004; 9: 698-704.
45. Walker RM, Christoforou A, Thomson PA, et al. Association analysis of neuregulin 1 candidate regions in schizophrenia and bipolar disorder. Neurosci Lett 2010; 478: 9-13.
46. Kampman O, Anttila S, Illi A, et al. Neuregulin genotype and medication response in Finnish patients with schizophrenia. Neuroreport 2004; 15: 2517-20.
47. Fareed M, Afzal M. Single nucleotide polymorphism in genome-wide association of human population: A tool for broad spectrum service. Egyp J Med Hum Genet 2013; 14: 123-34.
48. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-55.
49. Naz M, Riaz M, Saleem M. Potential role of Neuregulin 1 and TNFalpha (-308) polymorphism in schizophrenia patients visiting hospitals in Lahore, Pakistan. Mol Biol Rep 2011; 38(7): 4709-14.
50. Kontkanen O, Toronen P, Lakso MA, Wong G, Castren E. Antipsychotic drug treatment induces differential gene expression in the rat cortex. J Neurochem 2002; 83: 1043-53.
51. Corfas G, Roy K, Buxbaum JD. Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci 2004; 7(6): 575-80.
52. Margaret M, Rachel FT. Pharmacogenetics: A Tool for Identifying Genetic Factors in Drug Dependence and Response to Treatment. Addict Sci Clin Pract 2010; 5: 17-29.
53. Maria JA, Janet CM. Toward understanding genetic risk for differential antipsychotic response in individuals with schizophrenia. Expert Rev Clin Pharmacol 2011; 4: 389-405.
54. Mroziewicz M, Tyndale RF. Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. Addict Sci Clin Pract 2010; 5: 17-29.